Barclays assumed coverage on shares of INC Research (NASDAQ:INCR) in a research report sent to investors on Monday, Marketbeat reports. The firm issued an equal weight rating and a $40.00 price target on the stock.
Other research analysts also recently issued reports about the company. Zacks Investment Research upgraded INC Research from a hold rating to a buy rating and set a $58.00 target price for the company in a research note on Wednesday, September 27th. BidaskClub upgraded INC Research from a sell rating to a hold rating in a research note on Thursday, December 7th. Mizuho assumed coverage on INC Research in a research note on Thursday, September 21st. They issued a neutral rating and a $57.00 price target for the company. Jefferies Group upgraded INC Research from a hold rating to a buy rating and boosted their price target for the company from $62.50 to $69.00 in a research note on Monday, October 9th. Finally, Robert W. Baird restated a buy rating and issued a $67.00 price target on shares of INC Research in a research note on Monday, October 9th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company. The company currently has an average rating of Hold and a consensus price target of $51.40.
INC Research (NASDAQ:INCR) opened at $41.35 on Monday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.27 and a current ratio of 1.27. INC Research has a one year low of $33.60 and a one year high of $61.10. The company has a market capitalization of $4,366.84, a P/E ratio of 19.20, a PEG ratio of 1.32 and a beta of 1.08.
In other INC Research news, CEO Alistair Macdonald sold 2,348 shares of INC Research stock in a transaction on Monday, September 18th. The stock was sold at an average price of $54.60, for a total value of $128,200.80. Following the completion of the transaction, the chief executive officer now directly owns 99,453 shares of the company’s stock, valued at approximately $5,430,133.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Christopher L. Gaenzle sold 4,682 shares of INC Research stock in a transaction on Monday, September 18th. The shares were sold at an average price of $54.56, for a total value of $255,449.92. Following the completion of the transaction, the chief accounting officer now directly owns 60,579 shares of the company’s stock, valued at $3,305,190.24. The disclosure for this sale can be found here. Insiders sold a total of 16,733 shares of company stock valued at $912,270 over the last ninety days. Insiders own 0.24% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Lee Thomas H Partners LP acquired a new position in shares of INC Research during the 3rd quarter worth $1,316,644,000. Sei Investments Co. raised its holdings in shares of INC Research by 21.8% during the 3rd quarter. Sei Investments Co. now owns 230,989 shares of the company’s stock worth $12,081,000 after buying an additional 41,279 shares in the last quarter. Arizona State Retirement System acquired a new position in shares of INC Research during the 2nd quarter worth $1,336,000. Koch Industries Inc. acquired a new position in shares of INC Research during the 2nd quarter worth $499,000. Finally, Personal Capital Advisors Corp acquired a new position in shares of INC Research during the 3rd quarter worth $234,000. 99.56% of the stock is owned by institutional investors.
WARNING: This piece was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://stocknewstimes.com/2017/12/14/barclays-begins-coverage-on-inc-research-incr.html.
About INC Research
INC Research Holdings, Inc is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.
Receive News & Ratings for INC Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research and related companies with MarketBeat.com's FREE daily email newsletter.